Clik here to view.
Brief Items of Interest, April 2016
Hair loss news first: — We start with Samumed and its Turkish CEO Osman Kibar being featured in a Forbes magazine cover page story and article that everyone was talking about last week. Turkish media...
View ArticleClik here to view.
Brief Items of Interest, September 2016
Few days later than usual, but lots of new developments in the past month. Hair loss news first: — The most important news is courtesy of HLT, which several days ago interviewed people from the Dr....
View ArticleBrief Items of Interest, February 2017
Hair loss news first: — Update: Due to several people asking, I contacted Follica about their parent company Puretech’s latest presentation, and they sent me the following disappointing news: “Hi!...
View ArticleSamumed E-mail
Someone associated with Samumed just e-mailed me today (see blue text below for contents) and I was pleasantly surprised since I have not contacted the company anytime recently. The e-mail pertains to...
View ArticleBrief Items of Interest, April 2017
Hair loss news first: — A great story on Dr. Rox Anderson that was also retweeted by PureTech CEO Daphne Zohar: “Dermatologists don’t get the same accolades as brain surgeons/cancer warriors” Nice...
View ArticleSamumed to Initiate Phase 3 Clinical Trials
When it comes to a hair loss cure or groundbreaking new hair loss treatment, Samumed is one of the favorites to come out with something significant in the next several years. I have covered Samumed and...
View ArticleClik here to view.
A Truly Outstanding Week in Hair
As if my last post on Dr. Terskikh’s progress and new company was not enough, three other new developments occurred last week that were extremely encouraging. Follicum Positive Phase IIa Results “The...
View ArticleClik here to view.
Samumed’s Compound Structure
I have covered Samumed and its SM04554 compound to treat hair loss dozens of times in the past. Phase 3 Trials ending in 2020. Please use the categories menu of this blog to find my past posts on this...
View ArticleClik here to view.
Samumed Expects 2021 or early 2022 FDA Approval
I have covered Samumed (US) close to 20 times on this blog. In 2018, the company started Phase 3 clinical trials for its androgenetic alopecia (SM04554) topical product. Samumed pipeline. Androgenetic...
View ArticleClik here to view.
Biosplice Therapeutics: Rebrand of Samumed
Biosplice Therapeutics Logo. In a surprising twist, Samumed just rebranded itself as Biosplice Therapeutics (San Diego). CEO Osman Kibar has stepped down. The new CEO is Cevdet Samikoglu. In 2021, the...
View Article